Replimune Group, Inc. (REPL)
| Market Cap | 1.37B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -72.66M |
| Shares Out | 46.89M |
| EPS (ttm) | -1.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 204,545 |
| Open | 29.21 |
| Previous Close | 29.10 |
| Day's Range | 28.42 - 29.68 |
| 52-Week Range | 26.57 - 46.64 |
| Beta | 2.37 |
| Analysts | Buy |
| Price Target | 53.78 (+84.1%) |
| Earnings Date | Nov 4, 2021 |
About REPL
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, wh...
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for REPL stock is "Buy." The 12-month stock price forecast is 53.78, which is an increase of 84.05% from the latest price.
News
Replimune Appoints Christy Oliger to its Board of Directors
WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy pla...
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
RP1; Full patient accrual in CERPASS registration-directed clinical trial continues to be expected in mid-year 2022 with the primary data trigger expected in late 2022. Interim data in the IGNYTE anti-P...
Replimune Announces Presentations at the 2021 Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
WOBURN, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today anno...
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
Updated complete and durable response data in RP1 (vusolimogene oderparepvec) skin cancer cohorts support the ongoing registration directed development programs in CSCC and anti-PD-1 failed melanoma, wi...
Replimune to Present at Two Upcoming Investor Conferences
WOBURN, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today anno...
Replimune to Present at the William Blair Biotech Focus Conference 2021
WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today anno...
Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expan...
High rate of complete responses in RP1 skin cancer cohorts underscore the potential for profound patient benefit and supports the ongoing registration directed development programs
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update
Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC and held Type B meeting with FDA to discuss the IGNYTE study in anti-PD1 failed melanoma
Replimune Appoints Tanya Lewis as Chief Development Operations Officer
WOBURN, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today annou...
Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination w...
WOBURN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today annou...
Replimune to Host Virtual Investor Event on June 3, 2021
Event to begin at 8:00 AM ET Event to begin at 8:00 AM ET
Analysts See Plenty of Upside for Replimune
Boston-area biotech Replimune Group Inc. (NASDAQ:REPL) just boosted its executive lineup with a heavy hitter, and the market seems to like the addition.
Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American...
Data confirms potent anti-tumor activity & activation of robust systemic immune responses by RP1 and RP2
3 Biotech Stocks That Could Double In 12 Months
Biotech stocks are risky investment bets that can swing an investor's fortunes in a big way. An investment decision backed by careful scrutiny and analysis — of a company's pipeline, collaborations, fun...
Replimune to Present at the American Association for Cancer Research Annual Meeting 2021
WOBURN, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today ann...
Replimune to Present at Three Upcoming Investor Conferences
WOBURN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today ann...
Replimune to Present at the SVB Leerink 10th Annual Global Healthcare Conference
WOBURN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today anno...
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
RP1: Initial data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across al...
2 Biotech Stocks That Could Have Tripled Your Money This Year
One has a better chance to keep climbing than the other does.
2 Top Biotech Stocks From the IPO Class of 2018 to Buy Now
Compelling clinical trial results so far make these biotech stocks worth more attention than they've received so far.
Replimune Announces Pricing of Upsized Public Offering
BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced t...
Replimune Announces Proposed Public Offering
BOSTON, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced a...
Replimune Releases Updated Corporate Presentation
WOBURN, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced ...
Replimune Appoints Tanya Lewis to the Board of Directors
WOBURN, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today anno...
Why Replimune Stock Is Soaring Today
The company plans to present encouraging early-stage clinical data at a major conference next month.